Angel Invest Boston

Angel Scale Biotech: Learn More   Layne Sadler founded KeyBio to help pharmaceutical companies better identify genetic traits in patients that may explain differing responses to cancer treatments. KeyBio’s computational approach promises to add a new dimension to precision medicine, which now looks at the genetics of the tumor, by also incorporating the genetics of the patient to improve outcomes in clinical trials.   Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson.   Highlights: Sal Daher Introduces Layne Sadler What KeyBio is Solving "... The revenue is solely focused on cancer drug discovery and the reason for that is because that's where all the money is in the pharmaceutical industry..." "... 90% of clinical trials fail and the cost averages around 792 million, spending about a billion dollars to run a trial..." "... I developed this AI platform and I wanted to start collaborating with other principal investigators or heads of labs in the Boston a